Work

Neuropsychiatric long COVID is associated with altered SARS-CoV-2-specific cellular-humoral coordination and diminished EBV-specific humoral immunity up to 12 months post-COVID-19 symptom onset

Year: 2026
Type: article
Study design: Observational Study
Abstract: Long COVID is a chronic multisystemic condition estimated to affect approximately 400 million people worldwide. Although underlying mechanisms remain elusive, persistent SARS-CoV-2 reservoirs and Epstein-Barr virus (EBV) reactivation have been implicated. We compared SARS-CoV-2- and EBV-specific cellular and humoral immunity between 27 long COVID individuals with ≥2 neuropsychiatric symptoms and 27 matched recovered participants at 3-6 months post-COVID-19 symptom onset (PSO). Peripheral blood mononuclear cells were assessed for IFN-γ, IL-2, TNF, and granzyme B T-cell responses against SARS-CoV-2, EBV, and HCMV. Sera were evaluated for neutralizing activity against live ancestral SARS-CoV-2 and EBV, while EBV reactivation was assessed by anti-early antigen-diffuse IgG and anti-viral capsid antigen (VCA) IgM. We observed no significant differences in SARS-CoV-2-, EBV-, or HCMV-specific Th1-type/cytotoxic T-cell responses or live virus neutralization between long COVID and recovered groups at 3-6 months PSO. Although SARS-CoV-2-specific IFN-γ and IL-2 T-cell responses correlated with serological neutralizing capacity in recovered participants, no such associations were observed in the long COVID group, suggesting altered coordination between cellular and humoral immunity. EBV reactivation was only detected in one neuropsychiatric long COVID participant. However, EBV anti-VCA IgG antibody levels were significantly diminished in long COVID participants at 3-6 months PSO. Reports of fatigue at 12 months PSO were also associated with reduced EBV neutralizing capacity at 3-6 months PSO. Diminished EBV-specific humoral immunity and dysregulated coordination between SARS-CoV-2-specific cellular and humoral immunity may thus represent potential prognostic markers for neuropsychiatric long COVID development and fatigue up to 12 months PSO.IMPORTANCEWe performed a comprehensive analysis of cellular and humoral immune responses to SARS-CoV-2, Epstein-Barr virus (EBV), and human cytomegalovirus in individuals with neuropsychiatric long COVID, a subgroup that remains poorly characterized. Although no differences in virus-specific Th1-type or cytotoxic T-cell immunity were observed between individuals with long COVID and recovered individuals, altered coordination between SARS-CoV-2-specific T-cell and neutralizing humoral immunity was observed in the long COVID group at 3-6 months post-COVID-19 symptom onset (PSO). Diminished EBV-specific humoral immunity was also associated with neuropsychiatric long COVID and fatigue up to 12 months PSO. Together, these findings suggest that altered SARS-CoV-2-specific cellular-humoral immune coordination and diminished EBV-specific humoral immunity may contribute to the development or persistence of neuropsychiatric long COVID and highlight a promising future direction for mechanistic studies.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT05125510.
Language: English
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7125918652
FWCI:
Cites: 68
Cited by:
Related to: 10